Background: cervical cancer is the third leading cause of female deaths worldwide, and it is the leading cause of female deaths in developing countries. A routine survival evaluation is required to imply the result of the treatment. The aim of this study was to determine the cervical cancer patient survival rate at the Cipto Mangunkusumo hospital as national referral hospital in Indonesia.
Methods: our retrospective cohort study utilized the medical records of cervical cancer patients from 2012 to 2014 using total population sampling method. The data analysis was conducted using the Kaplan-Meier curve, log rank test and Cox regression to determine significant associations between variables.
Results: there were 1,303 subjects with overall survival rates of cervical cancer up to the fifth year of 76%, 65%, 59%, 43% and 34%, respectively, with a median survival of 1,316 days. There were significant differences of hazard ratio for cancer stage variables (p<0.001), and the Cox regression analysis showed that the factor affecting survival was cancer stage.
Conclusion: the 5-year cervical cancer survival rate at the Cipto Mangunkusumo hospital from 2012 to 2014 was 34%.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The ability of clostridium novyi-NT spores to induce apoptosis via the mitochondrial pathway in mice with HPV-positive cervical cancer tumors derived from the TC-1 cell line.
BMC Complement Med Ther
December 2024
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: A precise observation is that the cervix's solid tumors possess hypoxic regions where the oxygen concentration drops below 1.5%. Hypoxia negatively impacts the host's immune system and significantly diminishes the effectiveness of several treatments, including radiotherapy and chemotherapy.
View Article and Find Full Text PDFU.parvum serovar 6 may be a novel element in the progression of HPV infection to CIN: A cross-sectional study of 7,058 women.
J Infect
December 2024
Microbiome Medicine Centre, Department of Laboratory Medicine, ZhuJiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Background: Ureaplasma parvum (U. parvum) is generally regarded as innocuous, and studies focusing on variations in pathogenicity among U. parvum serovars are inadequate.
View Article and Find Full Text PDFCorrection: The role of the SOX2 gene in cervical cancer: focus on ferroptosis and construction of a predictive model.
J Cancer Res Clin Oncol
December 2024
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315000, China.
Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.
Int J Gynaecol Obstet
December 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Objective: In Japan, the current coverage rate of human papillomavirus (HPV) vaccination is only 30%, and the rate of biennial cervical screening is 40%. The Japanese Government has attempted to increase the coverage of HPV vaccination and cervical screening. We analyzed the cost-effectiveness of the 9-valent HPV vaccine and cervical screening in Japan.
View Article and Find Full Text PDF<b>Background and Objective:</b> Cervical cancer is the second most common cancer in Indonesia, where traditional herbal treatments like <i>Zanthoxylum acanthopodium</i> (andaliman) are culturally used. Investigating protein biomarkers such as E7, pRb, EGFR and p16 can help assess the efficacy of these treatments. <b>Materials and Methods:</b> There were 5 groups in this study: 2 control groups (C- and C+) and 3 treatment groups (each receiving one of three doses).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!